A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced müller cell disruption

Shen W., Lee S.-R., Yam M., Zhu L., Zhang T., Pye V., Mathai A.E., Shibagaki K., Zhang J.-Z., Matsugi T., Gillies M.C.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

The University of Sydney, Save Sight Institute Discipline of Ophthalmology, Sydney Medical School, Sydney, NSW, Australia; Department of Non-Clinical Research, Global R&D, Santen Pharmaceutical Co. Ltd., Nara, Japan

Related Publications

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.

Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.

View all Back of the eye (BOTE) publications